Showing 161-170 of 2152 results for "".
COLLAB CORNER - Integrating New Technology Into Practice
https://modernod.com/podcasts/collaborative-corner-the-podcast/collab-corner-integrating-new-technology-into-practice/39857/Marc R. Bloomenstein, OD, FAAO, invites Ryan Corte, OD, to the podcast to share his experience launching his podcast, building his personal and practice brands, and facilitating the education and mentorship of younger optometrists. Dr. Corte shares advice for how young optometrists can gain advantagOD-OD Relationships: A Surgical Story
https://modernod.com/topics/cataractrefractive-surgery/od-od-relationships-a-surgical-story/39155/col·lab·o·rate — to work jointly with others or together especially in an intellectual endeavorCOLLAB CORNER - What’s Coming Down the Pipeline in Patient Care
https://modernod.com/podcasts/collaborative-corner-the-podcast/whats-coming-down-the-pipeline-in-patient-care/54780/In this episode, Marc Bloomenstein, OD, FAAO, talks with Mitch Ibach, OD, FAAO, who practices at Vance Thompson Vision, in Sioux Falls, South Dakota, an OD-MD tertiary referral center. The pair opened the conversation with what’s new and exciting in patient care, including a newly-approved presbyopiTakeways From the TFOS DEWS III Report
https://modernod.com/podcasts/to-the-point/takeways-from-the-tfos-dews-iii-report/36948/In this episode of To the Point, Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, MS, MBA, FAAO, get into a deep discussion with Vin T. Dang, OD, FAAO, on the recent Tear Film & Ocular Surface Society Dry Eye Workshop (TFOS DEWS) III Report. Dr. Dang shares his top takesaways from the report anSleep + DED • Motivating Staff
https://modernod.com/podcasts/the-mod-pod/sleep-ded-motivating-staff/36878/This month on The MOD Pod, host Cecelia Koetting, OD, FAAO, Dipl ABO, welcomes guests Josh Davidson, OD, FAAO, FSLS, and Marlon Monelyon-Demeritt, OD, MBA, FAAO. Dr. Koetting and Dr. Davidson discuss the relationship between sleep and risk level of dry eye disease, with Dr. Davidson citing studies tHow to Add Dry Eye Research to Your Clinical Life
https://modernod.com/podcasts/to-the-point/how-to-add-dry-eye-research-to-your-clinical-life/36940/Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, MBA, MS, FAAO, are joined by Sathi Maiti, OD, FAAO, who shares her knowledge and experience working on dry eye clinical research. Dr. Maiti offers great advice on what you need to know before seeking out a clinical trial, how to delegate tasks to youOptometric Rights • Myopia • MGD
https://modernod.com/podcasts/the-mod-pod/optometric-rights-myopia-mgd/36824/To start off the episode, Rasika Whitesell, OD, talks about how optometric legislation, particularly that affecting scope of practice, can be changed without OD knowledge or approval (00:48). Vittorio Mena, OD, MS, and co-author Katie Connolly, OD, FAAO, then discuss guidelines for managing myopia (Continuing the Dry Eye Conversation
https://modernod.com/podcasts/to-the-point/continuing-the-dry-eye-conversation/54334/Kicking off the first episode of the To the Point podcast in 2026, co-hosts Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, FAAO, continue the dry eye conversation with DED pearls to implement in clinic. They cover everything from patient signs, symptoms, and side effects to in-office tools, treatAn Interview With the Inventor of Rinsada
https://modernod.com/podcasts/to-the-point/an-interview-with-the-inventor-of-rinsada/36934/Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, MBA, MS, FAAO, are joined by retina specialist Srinivas Kondapalli, MD, who developed the Rinsada Irrigating Lid Retractor, which effectively cleanses the conjunctival fornix, palpebral conjunctiva, and bulbar conjunctiva.Considerations for Use of Two Newly Approved Drugs
https://modernod.com/podcasts/to-the-point/considerations-for-use-of-two-newly-approved-drugs/36928/Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, MBA, MS, FAAO, discuss factors to consider when bringing perfluorohexyloctane ophthalmic solution (Miebo, Bausch + Lomb) and lotilaner ophthalmic solution 0.25% (Xdemvy, Tarsus Pharmaceuticals) into your clinical practice.